×
About 16,653 results

ALLMedicine™ Alopecia Center

Research & Reviews  4,404 results

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT03898479

Mar 31st, 2023 - The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata.

A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT04784533

Mar 31st, 2023 - This is a two part, double-blind, randomized, multicenter study to evaluate the regrowth of hair with CTP-543 and subsequent durability of that regrowth following dose reduction in adult patients with moderate to severe alopecia areata.

European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT05041803

Mar 31st, 2023 - The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata. Patients from European sites who p...

A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT03570749

Mar 30th, 2023 - This study is designed to select up to two doses of baricitinib (referred to as low dose and high dose) and assess their efficacy and safety for the treatment of severe or very severe alopecia areata. An additional subpopulation of 60 participants...

A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT05723198

Mar 29th, 2023 - The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age. The study is divided into 4 periods...

see more →

Guidelines  3 results

Guidelines for the diagnosis and treatment of male-pattern and female-pattern hair loss...
https://doi.org/10.1111/1346-8138.14470
The Journal of Dermatology; Manabe M, Tsuboi R et. al.

Jun 5th, 2018 - Male-pattern hair loss (MPHL, androgenetic alopecia) is a slowly progressive form of alopecia which begins after puberty. In 2010, we published the first Japanese edition of guidelines for the diagnosis and treatment of MPHL. It achieved the origi...

Guidelines for management of androgenetic alopecia based on BASP classification--the As...
https://doi.org/10.1111/jdv.12034
Journal of the European Academy of Dermatology and Venere... Lee WS, Lee HJ et. al.

Nov 28th, 2012 - Androgenetic alopecia (AGA), or pattern hair loss, is a common disorder in both Asian men and women. There are several guidelines for the treatment of AGA which are suitable for Caucasian patients; however, each of these has some limitations. Furt...

British Association of Dermatologists' guidelines for the management of alopecia areata...
https://doi.org/10.1111/j.1365-2133.2012.10955.x
The British Journal of Dermatology; Messenger AG, McKillop J et. al.

Apr 25th, 2012 - British Association of Dermatologists' guidelines for the management of alopecia areata 2012.|2012|Messenger AG,McKillop J,Farrant P,McDonagh AJ,Sladden M,|diagnosis,etiology,therapy,methods,therapeutic use,methods,methods,methods,

see more →

Drugs  496 results see all →

Clinicaltrials.gov  470 results

European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT05041803

Mar 31st, 2023 - The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata. Patients from European sites who p...

A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT04784533

Mar 31st, 2023 - This is a two part, double-blind, randomized, multicenter study to evaluate the regrowth of hair with CTP-543 and subsequent durability of that regrowth following dose reduction in adult patients with moderate to severe alopecia areata.

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT03898479

Mar 31st, 2023 - The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata.

A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT03570749

Mar 30th, 2023 - This study is designed to select up to two doses of baricitinib (referred to as low dose and high dose) and assess their efficacy and safety for the treatment of severe or very severe alopecia areata. An additional subpopulation of 60 participants...

A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT05723198

Mar 29th, 2023 - The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age. The study is divided into 4 periods...

see more →

News  1,262 results

Severe atopic dermatitis linked with significant overall morbidity
https://www.mdedge.com/dermatology/article/261946/atopic-dermatitis/severe-atopic-dermatitis-linked-significant-overall

Mar 23rd, 2023 - Key clinical point: Compared with mild atopic dermatitis (AD), severe AD results in an increased risk for overall morbidity. Major finding: Patients with severe vs mild AD had a significantly increased risk for other dermatitis, extragenital herpe.

New Lupus Drug Cuts Skin Disease When Other Agents Fail
https://www.medpagetoday.com/rheumatology/lupus/103537

Mar 15th, 2023 - Every patient with discoid lupus erythematosus (DLE) that had not responded to multiple standard medications showed substantial improvement when put on anifrolumab (Saphnelo) in a small retrospective study, researchers said. Among eight patients t...

Painful blue fingers
https://www.mdedge.com/familymedicine/article/261715/immunology/painful-blue-fingers
MDedge Family Medicine; Arissa Young, MD, Marian Kaldas, MD et. al.

Mar 9th, 2023 - A 48-year-old woman with a history of systemic lupus erythematosus (SLE) presented to the emergency department from the rheumatology clinic for digital ischemia. The clinical manifestations of her SLE consisted predominantly of arthralgias, which.

Dermatologic Implications of Sleep Deprivation in the US Military
https://www.mdedge.com/dermatology/article/261677/atopic-dermatitis/dermatologic-implications-sleep-deprivation-us-military
Erika J. Anderson, MD, Jonathan P. Jeter, MD

Mar 8th, 2023 - Sleep deprivation can increase emotional distress and mood disorders; reduce quality of life; and lead to cognitive, memory, and performance deficits. 1 Military service predisposes members to disordered sleep due to the rigors of deployments and f.

The Evidence Behind Topical Hair Loss Remedies on TikTok
https://www.mdedge.com/dermatology/article/261558/hair-nails/evidence-behind-topical-hair-loss-remedies-tiktok
Aaminah F. Azhar, MD

Mar 2nd, 2023 - Hair loss is an exceedingly common chief concern in outpatient dermatology clinics. An estimated 50% of males and females will experience androgenetic alopecia.

see more →

Patient Education  26 results see all →